AstraZeneca Halts Marketing of Covid-19 Vaccine Vaxzevria in EU Due to Oversupply and Decrease in Demand

AstraZeneca has announced that it will halt the marketing of its Covid-19 vaccine, Vaxzevria, in the European Union starting from tomorrow. The company made this decision after assessing the current market and realizing that there is an oversupply of vaccines, leading to a decrease in demand for Vaxzevria.

In a statement, AstraZeneca confirmed that they have submitted a withdrawal request to the European Commission, who have confirmed that they will withdraw the marketing authorization for the drug at their request. The company stated that with the availability of numerous updated vaccines for Covid-19 variants, there is now a surplus of vaccines on the market, leading to a decrease in demand for Vaxzevria, which is no longer being produced or supplied.

The decision to stop marketing Vaxzevria is a strategic move by AstraZeneca in response to the changing landscape of the vaccine market. Despite this decision, AstraZeneca acknowledges the impact that Vaxzevria has had in saving lives and supplying vaccines worldwide. It played an important role in combatting the pandemic and has saved over 6.5 million lives and supplied more than 3 billion doses globally in its first year of use.